Study of HRS-4029 for acute ischemic stroke
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests a new drug, HRS-4029, given within 3 hours of an ischemic stroke (a stroke caused by a blocked blood vessel). The goal is to see if the drug helps improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had an ischemic stroke within the last 3 hours.
- You must have had little or no disability before the stroke.
- Your stroke symptoms must be moderate to moderately severe, with some weakness in an arm or leg.
- You must be able to receive the study drug within 3 hours of the stroke starting.
- You cannot have had bleeding in the brain or certain major heart problems recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a single dose of a new medicine called HRS-4029 in healthy people. It helps doctors learn how the drug works in the body and if it is safe. Healthy adults aged 18 to 55 may be able to join.
This trial tests whether MT200605 can help people who recently had an ischemic stroke (a type of stroke caused by a blocked blood vessel). The drug is given within 24 hours of symptoms starting, and you may join even if you received clot-busting treatment already.
This trial tests an investigational drug called LT3001 for people who have had an acute ischemic stroke (a type of stroke caused by a blocked blood vessel in the brain). The drug is given within 24 hours of the stroke to help reduce the damage and improve recovery. Participating could offer access to a new treatment option that may help improve outcomes.
This trial tests an investigational drug called B2065 for people who have had a recent ischemic stroke (a stroke caused by a blockage in a blood vessel in the brain). The goal is to see if it is safe and if it might help improve recovery when given within 36 hours of stroke symptoms starting.
This trial tests if adding a drug called human urinary kallidinogenase (HUK) can improve recovery for people who have had a stroke and already received clot-busting medicine or a procedure to remove the clot. The goal is to see if it helps reduce disability after a stroke.
This trial tests an investigational drug, QHRD106, given as an injection for people who have had a moderate-to-severe acute ischemic stroke. It aims to see if the drug can help recovery when given within 24 hours after the stroke starts, and it is for patients who are not receiving standard clot-busting treatment.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.